Markedly increased serum erythropoietin levels following conditioning for allogeneic bone marrow transplantation
- PMID: 2207449
Markedly increased serum erythropoietin levels following conditioning for allogeneic bone marrow transplantation
Abstract
Serum erythropoietin (EPO) levels were measured by radioimmunoassay in 36 patients undergoing allogeneic bone marrow transplantation (BMT). Serum EPO levels before conditioning treatment for BMT were generally higher than the levels obtained from healthy controls (49 +/- 17 (SEM) and 17 +/- 0.6, respectively). One day prior to BMT, after conditioning by chemotherapy with or without total body irradiation, the mean EPO level was markedly elevated (218 +/- 23 U/l, p less than 0.001) and reached to its highest level at 1 week post-BMT (269 +/- 40 U/l). Although, the EPO levels were significantly lower at 1 month (98 +/- 24 U/l, p less than 0.001), they were still elevated up to 3 months post-BMT, after which they gradually normalized. Patients given methotrexate and cyclosporine for prophylaxis against graft-versus-host disease (GVHD) had significantly lower EPO levels during the first 3 months post-BMT than patients transplanted with T cell-depleted marrow (p less than 0.05). Patients with post-transplant nephrotoxicity had lower, though not statistically significant, EPO levels than patients with normal renal function (p = 0.07). Acute GVHD and number of blood transfusions had no influence on serum EPO levels after BMT.
Similar articles
-
CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.Biol Blood Marrow Transplant. 1997 Apr;3(1):11-7. Biol Blood Marrow Transplant. 1997. PMID: 9209736
-
Bone marrow transplantation in children: consequences for renal function shortly after and 1 year post-BMT.Bone Marrow Transplant. 1998 Sep;22(6):559-64. doi: 10.1038/sj.bmt.1701388. Bone Marrow Transplant. 1998. PMID: 9758343
-
Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.Bone Marrow Transplant. 1999 Mar;23(5):443-50. doi: 10.1038/sj.bmt.1701493. Bone Marrow Transplant. 1999. PMID: 10100557 Clinical Trial.
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
-
The use of erythropoietin in the treatment of post-bone marrow transplantation anemia.Int J Artif Organs. 1993 Dec;16 Suppl 5:8-12. Int J Artif Organs. 1993. PMID: 8014003 Review.
Cited by
-
Clinical use of rHuEPO in bone marrow transplantation.Med Oncol. 1999 Apr;16(1):2-7. doi: 10.1007/BF02787351. Med Oncol. 1999. PMID: 10382935 Review.
-
Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer.Cochrane Database Syst Rev. 2019 Mar 11;3(3):CD008944. doi: 10.1002/14651858.CD008944.pub3. Cochrane Database Syst Rev. 2019. PMID: 30855726 Free PMC article.
-
Inadequate erythropoietin response to anemia: definition and clinical relevance.Ann Hematol. 1994 May;68(5):215-23. doi: 10.1007/BF01737420. Ann Hematol. 1994. PMID: 8018762 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials